ACADIA Announces Pimavanserin Meets Primary and Key Secondary Endpoints in Pivotal Phase III Parkinson’s Disease Psychosis Trial

Pimavanserin Demonstrates Highly Significant Antipsychotic Efficacy and Maintenance of Motor Control in Parkinson’s Patients
Significant Improvements Also Observed in All Secondary and Exploratory Measures

ACADIA Pharmaceuticals Inc. (ACAD) today announced successful top-line results from its pivotal Phase III trial evaluating the efficacy, tolerability and safety of pimavanserin in patients with Parkinson’s disease psychosis (PDP). Pimavanserin is ACADIA’s proprietary, non-dopaminergic product candidate that selectively blocks serotonin 5-HT2A receptors. Pimavanserin met the primary endpoint in the Phase III trial by demonstrating highly significant antipsychotic efficacy as measured using the 9-item SAPS-PD scale (p=0.001). Pimavanserin also met the key secondary endpoint for motoric tolerability as measured using Parts II and III of the Unified Parkinson’s Disease Rating Scale, or UPDRS.

Published: 27 November 2012
Written by Editor
Nasdaq   Healthcare   Project Updates   Up on News   Interesting News  
Read more: ACADIA Pharmaceuticals Inc ( ACAD )

Galectin Therapeutics Receives US Patent for Second Drug Class to Treat Chronic Liver Disease with Fibrosis (Scarring) and Cirrhosis

Galectin Therapeutics (GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that it has received a notice of allowance from the U.S. Patent and Trademark Office for a divisional patent of Patent Number 8,236,780 “Galactose-prolonged polysaccharides in a formulation for antifibrotic therapies”. The patent covers key methods of derivation and use for the Company’s galactomannan-based carbohydrate galectin inhibitor compounds, for use in patients with chronic liver disease associated with the development of fibrosis, established liver fibrosis or end-stage scarring, or cirrhosis. Fibrotic disease of the liver is highly prevalent in the population because all chronic liver diseases, including viral hepatitis, fatty liver and alcohol abuse, result in fibrosis of the liver for which there are no currently approved pharmaceutical therapies.

Published: 26 November 2012
Written by Editor
Nasdaq   Healthcare   Project Updates   Up on News   Interesting News  
Read more: Galectin Therapeutics ( GALT )

EntreMed Announces Publication Of Preclinical Results For ENMD-2076 In Triple-negative Breast Cancer

Predictive biomarkers of sensitivity to ENMD-2076 published in Clinical Cancer Research

EntreMed, Inc. (ENMD), a clinical-stage pharmaceutical company developing targeted therapeutics for the treatment of cancer, announced today the publication of favorable results of a preclinical study in breast cancer of its oral Aurora A/angiogenic kinase inhibitor, ENMD-2076. 

Published: 26 November 2012
Written by Editor
Nasdaq   Healthcare   Project Updates   Up on News   Interesting News  
Read more: EntreMed Inc ( ENMD )

MAP Pharmaceuticals Announces FDA Acceptance for Filing of NDA Resubmission for LEVADEX®

--New PDUFA date April 15, 2013--

MAP Pharmaceuticals, Inc. (MAPP) today announced that its New Drug Application (NDA) resubmission for LEVADEX® orally inhaled migraine drug for the potential acute treatment of migraine in adults has been accepted for filing by the U.S. Food and Drug Administration (FDA).  The FDA has classified the resubmission as a complete, Class 2 response to the FDA's March 26, 2012 action letter and has set a goal date of April 15, 2013 under the Prescription Drug User Fee Act.

Published: 23 November 2012
Written by Editor
Nasdaq   Healthcare   FDA HC Decision   Up on News   Interesting News  
Read more: MAP Pharmaceuticals Inc ( MAPP )

A Single Dose of Medicago's H5N1 VLP Vaccine Protects Against Additional Pandemic Flu Strains in a Preclinical Study

- First Demonstration of Cross-Protection Against H2N2 Influenza and a Different H5N1 Strain -

Medicago Inc. (TSX: MDG; OTCQX: MDCGF), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced results from an independent preclinical study on the cross-protection effects of Medicago's H5N1 VLP vaccine candidate ("H5N1 VLP vaccine").

Published: 20 November 2012
Written by Editor
TSX   Healthcare   Project Updates   Up on News   Interesting News  
Read more: Medicago Inc ( MDG )
  1. Cipher Pharmaceuticals Inc ( DND )
  2. Prana Biotechnology ( PRAN )
  3. AcelRx Pharmaceuticals Inc ( ACRX )
  4. Synergy Pharmaceuticals Inc ( SGYP )
  5. Gilead Sciences ( GILD )